Department of Physiotherapy, Faculty of Health Science, University of Málaga, Málaga, Spain.
Department of Medical Oncology, Carlos Haya Regional University Hospital, IBIMA, Málaga, Spain.
BMC Complement Altern Med. 2018 Jun 11;18(1):180. doi: 10.1186/s12906-018-2236-3.
Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by about 30% compared with tamoxifen while treatments differ. Unfortunately, nearly half of women taking AIs report AI-associated arthralgia (AIA), leading to therapy abandon in on third of patients, which could lead to cancer recurrence. The purpose of the current study was to evaluate the effectiveness of Neuromuscular Taping (NMT) in the treatment of AIA in women who have been treated of BC.
This study included 40 BC survivors receiving endocrine therapy (either AIs or TMX) from Hospital Universitario Virgen de la Victoria (Málaga, Spain) suffered from AIA. Patients were randomized to one of the two groups that made this pilot study: A. Placebo intervention B. Real NMT. Clinical data were collected from medical history, grip strength, algometry measured, questionnaires and VAS scale. There have been three interventions prior to the completion of the study, 5 weeks later. The primary objective of this pilot study was to achieve an improvement of pain by 20% decrease of VAS.
Significant differences in measures of VAS (p = 0.009), global health status/QoL (p = 0.005), fatigue (p = 0.01) and pain (p = 0.04) were observed post intervention with NMT.
An intervention by NMT to MSCM under treatment with AIs improves their subjective sensation of pain. In addition, this taping had an impact on variables related to the quality of life. This pilot study may be the basis for others to support the use of NMT for the treatment of AIAs, thereby improving their well-being and reducing the dropout rate.
ClinicalTrials.gov Identifier: NCT02406794 . Registered on 2 April 2015 Retrospectively registered.
与他莫昔芬相比，芳香化酶抑制剂可使绝经后妇女的乳腺癌复发率降低约 30%，但治疗方法不同。不幸的是，近一半接受 AI 治疗的女性报告称出现芳香化酶抑制剂相关的关节痛（AIA），导致三分之一的患者停止治疗，这可能导致癌症复发。本研究的目的是评估神经肌肉贴扎（NMT）在接受过 BC 内分泌治疗（AI 或 TMX）的 40 名 BC 幸存者中治疗 AIA 的有效性。
这项研究包括来自西班牙马拉加大学 Virgen de la Victoria 医院（西班牙马拉加）的 40 名接受内分泌治疗（AI 或 TMX）的 BC 幸存者患有 AIA。患者被随机分为两组进行这项初步研究：A. 安慰剂干预 B. 真实 NMT。临床数据从病史、握力、压痛计测量、问卷和 VAS 量表中收集。在完成研究之前进行了三次干预，在 5 周后完成。这项初步研究的主要目的是通过降低 20%的 VAS 来实现疼痛的改善。
NMT 干预后 VAS（p=0.009）、总体健康状况/生活质量（p=0.005）、疲劳（p=0.01）和疼痛（p=0.04）的测量值有显著差异。
用 NMT 对 MSCM 进行干预可改善其主观疼痛感觉。此外，这种贴扎对与生活质量相关的变量有影响。这项初步研究可能为其他支持使用 NMT 治疗 AIAs 的研究提供依据，从而改善其生活质量并降低退出率。
ClinicalTrials.gov 标识符：NCT02406794。于 2015 年 4 月 2 日注册，回顾性注册。
Zotero 插件
